Myeloid malignancies are characterized by genetic alterations either on the cytogenetic level and/or on the molecular genetic level. A large spectrum of chromosome aberrations and molecular mutations has been identified. These genetic abnormalities lead to alterations of pathways involved in cell proliferation, differentiation and apoptosis. Alterations of the RAS pathway have an important role in the pathogenesis of myeloid malignancies and occur either by activating mutations in RAS itself or by mutations in genes involved in the RAS-dependent pathways, such as FLT3, KIT or CBL. The NF1 gene encodes neurofibromin 1, a Ras-specific guanosine triphosphatase-activating protein that negatively regulates the p21ras (Ras) family of signaling proteins by accelerating GTP hydrolysis to inactive Rasguanosine diphosphate. Therefore, as NF1 is a negative regulator of RAS signaling, loss of NF1 function is likely to be functionally equivalent to an activating RAS gene mutation. Germline loss-offunction mutations of NF1 lead to neurofibromatosis type I. Carriers of the mutations develop benign neurofibromas and are predisposed not only to neuronal tumors but also to juvenile myelomonocytic leukemia, myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). In addition, in children suffering from chronic myelomonocytic leukemia (CMML) without germline NF1 mutations, acquired loss-of-function mutations of NF1 have been reported. The role of NF1 in adult myeloid malignancies has not been studied in detail so far. Recently, we identified cytogenetically cryptic 17q11 deletions encompassing the NF1 gene in 6 out of 37 AML cases with inv(16)(p13q22)/ t(16;16)(p13;q22). 1 17q11.2 deletions including the NF1 gene have also been detected by array comparative genomic hybridization (CGH) in 6 out of 100 consecutive de novo AML cases, 4 showing a complex aberrant karyotype and 2 an inv(16). 2 In a study by Rücker et al., 3 in 18 out of 60 AML with complex aberrant karyotype a commonly deleted region on 17p11 -17q11 between 23.1 and 29.5 Mb including the NF1 gene was identified by using array CGH. However, only few cases and only a limited number of exons have been investigated for NF1 mutations so far.
In order to analyze the role of NF1 in adult AML, we first evaluated NF1 gene expression in 272 AML cases using microarrays (HG-U133 Plus 2.0, Affymetrix, Santa Clara, CA, USA). These included cases with t(15;17)(q22;q12) (n ¼ 15), t(8;21)(q22;q22) (n ¼ 16), inv(16)(p13q22) (n ¼ 7), t(11q23)/ MLL-rearrangement (n ¼ 10), inv(3)(q21q26)/t(3;3)(q21;q26) (n ¼ 3), complex aberrant karyotype (n ¼ 47), normal karyotype (n ¼ 97) and with various other genetic abnormalities (n ¼ 77). The median NF1 expression intensity was 131.6 (range 35.2 -457.5). In all, 68 cases showed an expression intensity of NF1 below 98.6 (first quartile, low expression group) (Figure 1a) . In this cohort, cases with t(8;21) (n ¼ 10) or complex karyotype Letters to the Editor Table 1 Characteristics of patients with low NF1 expression and NF1 deletion from cohort 1, and of patients with NF1 deletion from cohort 2 (n ¼ 18) were over-represented (chi-square: Po0.0001 and P ¼ 0.021, respectively), whereas cases with normal karyotype (n ¼ 16) were under-represented (chi-square: Kasumi-1, HeLa and COS7-L) previously have demonstrated that the NF1 promoter is transcriptionally regulated by RUNX1, CEPBA and ETS2. Furthermore, as also shown by reporter assays, the RUNX1 -RUNX1T1 chimeric protein repressed the endogenous NF1 gene. 4 In addition to direct repression of transcription, a low NF1 expression could be due to a deletion of one NF1 gene copy. Therefore, we performed fluorescence in situ hybridization (FISH) analysis using a 420-kb probe spanning the NF1 gene (Kreatech, Amsterdam, The Netherlands) in 54/68 of cases with low NF1 expression with material available for FISH analysis. Remarkably, in 11/54 of these cases (20.4%) a NF1 deletion was identified by interphase FISH. This FISH assay detects only complete loss of the NF1 gene and is not able to identify small intragenic deletions. The median proportion of cells with NF1 deletion in individual cases was 90%, ranging from 60 to 99%. In the NF1 low expression group, the mean NF1 expression intensity in cases with NF1 deletion was lower as compared with that of cases with two NF1 copies (60.4 (s.d. ± 17.7) vs 75.5 (s.d. ±18.0); P ¼ 0.023). Chromosome banding analysis in the 11 cases with NF1 deletion revealed a complex karyotype (n ¼ 7, one of these cases with inv(3)(q21q26)), a normal karyotype (n ¼ 2), an inv(3)(q21q26) (n ¼ 1) and a 5q deletion accompanied by trisomy 21 (n ¼ 1), respectively. Details on patients with NF1 deletion are depicted in Table 1 .
To further investigate the incidence of NF1 deletion in myeloid malignancies, 889 additional patients were analyzed by FISH for NF1 deletion. A heterozygous NF1 deletion was observed in 46/889 (5.2%) patients. In detail, 23/315 (7.3%) de novo AML, 3/72 (4.2%) secondary AML, 4/25 (16%) therapyrelated AML, 7/176 (4.0%) CMML, 2/165 (1.2%) MDS and 7/136 (5.1%) MPN showed NF1 deletions (Figure 2 ). Detailed information on the patient cohort is depicted in Table 2 . The proportion of cells with NF1 deletion varied between 9 -98% (median 64%). A significant correlation was observed between bone marrow blast count and the proportion of cells with NF1 deletion (Spearman, r ¼ 0.512; P ¼ 0.006). Chromosome banding analysis in the NF1-deleted cases revealed a normal karyotype (6/509; 1.2%), an inv(16)(p13q22)/t(16;16)(p13;q22) (6/37; 16.2%), an inv(3)(q21q26)/t(3;3)(q21;q26) (3/27; 11.1%), a complex aberrant karyotype (n ¼ 19/62; 30.6%) or other abnormalities (12/162; 7.4%). The frequency of NF1 deletions was remarkably high in patients with inv(16)(p13q22)/ t(16;16)(p13;q22) and inv(3)(q21q26)/t(3;3)(q21;q26) (6 out of 37 analyzed cases (16.2%) and 3 out of 27 analyzed cases (11.1%), respectively), both subgroups are known to be associated with NRAS mutations.
1, 5, 6 The frequency of NF1 deletions in patients with complex aberrant karyotype was Further, next-generation deep sequencing (454 Life Sciences, Branford, CT, USA) was applied to study molecular mutations occurring in NF1 (transcript-ID: ENST00000358273). Genomic DNA used for mutational analyses was extracted from the purified fraction of mononuclear cells after Ficoll density centrifugation (QIAamp DNA Mini kit; Qiagen, Hilden, Germany). Peripheral blood (n ¼ 9) or bone marrow (n ¼ 20) specimens were collected between February 2006 and April 2010. The sequencing library preparation for the complete coding region, in total 61 amplicons with a median size of 343 bp, was performed using the small-volume Titanium chemistry assay. Primer pair sequences and PCR amplification protocol are available online (Supplementary Table 1 ). The data was analyzed using Sequence Pilot version 3.4 (JSI Medical Systems, Kippenheim, Germany). In 29/46 patients with NF1 deletions, sufficient material was available for mutation analysis. After excluding known polymorphisms and silent mutations (dbSNP resources; http://www.ncbi.nlm.nih.gov/projects/SNP), 19 distinct aberrations, that is, 11 point mutations (5 missense and 6 nonsense), 4 splice site mutations and 4 frame-shift mutations were detected in 15/29 (51.7%) patients. In more detail, we observed a median mutation load of 27% (range 3.7 -86.0%). The median coverage achieved was 510-fold (range 223 -1226-fold; Supplementary Table 1) . In all, 18/19 mutations observed using next-generation deep-sequencing (1/19 mutation detected by Sanger sequencing) were verified with an independent method, that is, using the Sanger sequencing technique (Supplementary Table 1 ). For 15/18 mutations, we were able to confirm the expected variant. Additionally, the remaining three cases (mutation load o10%) were validated and confirmed using 454 NGS in an independent PCR, emulsion PCR and sequencing run to exclude PCR errors (Supplementary Table 1 ).
Moreover, information on the clonality as detected by FISH analysis is given in the Supplementary Table 1. In a recently published study on 11 AML patients with NF1 deletions detected by SNP array analyses, two cases (18.2%) showed the NF1 mutation in the remaining allele by Sanger sequencing. 7 The impact of the loss of one NF1 allele is so far unclear. In our study on AML with CBFB -MYH11 rearrangement, we observed NF1 gene loss in six cases; two of these showed, in addition, an NRAS mutation and one case a KRAS mutation. These data suggest a cooperation of NF1 deletion and activating RAS mutations, leading together to hyperactive RAS signaling as an alternative mechanism to bi-allelic NF1 inactivation.
1 The low NF1 mutation load observed in six cases in this study can be interpreted as a step in evolution further activating RAS signaling, which might have an impact on resistance to chemotherapy.
In conclusion, NF1 deletions occur in 7.3% of de novo AML, 4% of CMML, 1.2% of MDS and 5.1% of MPN, and therefore are a frequent and important alternative genetic mechanism for activating the RAS pathway in adult myeloid malignancies. As the majority of NF1 deletions are not detectable by chromosome banding analysis because of the small size of the deletion, FISH analysis is required. Furthermore, in 15/29 patients (51.7%) with NF1 deletion as detected by FISH, a NF1 mutation was observed in the remaining allele. Data from cell culture models suggest that NF1 deficiency leads to AraC resistance in AML by upregulation of MEK and eIF4E activity, which results in enhancement of cell survival to overcome drug-induced apoptosis. This resistance can be reversed experimentally by exposure to a MEK inhibitor or an mTOR inhibitor. 7, 8 Future studies are necessary to determine the prognostic impact of NF1 deficiency caused by downregulation, deletion and/or mutation on the various subtypes of myeloid malignancies, as in this study the number of cases with NF1 deletion was not sufficient to determine the impact on outcome.
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Letters to the Editor
Significant advances have been made in the therapeutic landscape of Multiple Myeloma (MM) in the past decade with the introduction of novel therapies such as thalidomide, lenalidomide and the proteasome inhibitor bortezomib. 1-3 These drugs have improved survival in MM, but without a definite cure. 4 Pomalidomide is the newest immunomodulatory drug to be evaluated in clinical trials and has shown considerable efficacy. 5, 6 Phase I/II trials of pomalidomide combined with lowdose dexamethasone have reported partial response (PR) rates of 29-63% in relapsed MM, including in patients refractory to other IMiDs or bortezomib.
7-10 It is not clear how patients respond to existing therapies, once the disease becomes refractory to pomalidomide. We examined this question among patients receiving pomalidomide therapy in a phase 2 trial.
Patients enrolled in an ongoing phase 2 trial of pomalidomide and dexamethasone for relapsed myeloma, who subsequently have gone off study for disease progression, form the study population. 7, 8 Several cohorts of patients (X3 prior therapies not specified, lenalidomide refractory and lenalidomide and bortezomib refractory patients) were enrolled sequentially in this trial. 7, 11 Details of subsequent therapies and survival data were obtained from medical records. Approval from the Mayo Foundation Institutional Review Board was obtained in accordance with federal regulations and the Declaration of Helsinki.
Response to therapy was assessed using the International Myeloma Working Group (IMWG) uniform response criteria. The w 2 and Fisher's exact tests were used to compare differences between nominal variables and the Mann-Whitney U-test or Kruskal-Wallis test were used for continuous variables. KaplanMeier analysis was used to estimate survival, and differences between survival curves were tested for statistical significance using log-rank test.
A total of 74 patients from among 183 patients who had relapsed after pomalidomide were included in the study. The median age at the time of progression on pomalidomide was 63 (range: 39-89) years; 72% (53) were male. The median duration of pomalidomide therapy was 4.3 (range: 1-22) months and time from diagnosis to progression on pomalidomide was 5.0 (0.5-14) years. At the time of study entry, 61 (82%) patients were lenalidomide refractory, 39 (53%) patients were bortezomib refractory and 37 (50%) were refractory to both lenalidomide and bortezomib. The best confirmed response to pomalidomide was a PR or better in 21 (28%) patients and Minor Response (MR) or better in 37 patients (49%) in the study cohort. These results are in accordance with what has been reported before. 7, 11 At least one treatment was recorded for 52 (70%) patients following progression on pomalidomide. The most commonly used regimen following progression on pomalidomide contained bortezomib, including bortezomib with dexamethasone, with or without cyclophosphamide or melphalan (24; 46%). Overall, 24 patients had an MR or better (44%), including 16 (31%) patients with a PR or better to first therapy following relapse on pomalidomide (Table 1 ). These response rates are similar to what has been described in patients refractory to bortezomib and either thalidomide or lenalidomide in a multicenter study from IMWG.
12 Among the four patients receiving autologous stem cell transplantation (ASCT) as first therapy following progression on pomalidomide, three had a PR or better. An objective response of PR or better was seen in 6 (25%) patients treated with bortezomib-based regimen. Among the other regimens, lenalidomide-based regimens were instituted in seven patients; alkylator-steroid combination and VDT-PACE being employed in seven and six patients, respectively, achieving a confirmed response of PR or better in a third of the patients. The salvage regimens used in these patients reflect the current practice with many of the newer drugs being repeated. Previous studies have demonstrated that retreatment with bortezomib or IMiDs in patients previously exposed to these agents can be associated with clinically meaningful responses.
13,14 Patients experiencing relapse after long interval are likely to respond to same or similar regimens. For patients who have only a brief period of control, use of drugs with different mechanisms of action may overcome drug resistance to some extent.
Overall, 120 regimens were employed across 52 patients following progression on pomalidomide; median (range) number of regimens per patients was 1 (0-8). The response rates to the different regimens are shown in Table 1 . The most commonly used regimen was bortezomib-based in 43 (36%); followed by ASCT in 15 (13%), alkylator-steroid combination in 15 (11%), VDT-PACE in 14 (12%), and lenalidomide-based in
